<DOC>
	<DOCNO>NCT02348112</DOCNO>
	<brief_summary>The aim postmarket study compare safety effectiveness Altis Single Sling ( SIS ) FDA clear transobturator and/or retropubic sling 36 month .</brief_summary>
	<brief_title>Altis® 522 Trial - Treatment Female Stress Urinary Incontinence</brief_title>
	<detailed_description>This study prospective , post-market , multi-center , cohort assessment compare Altis SIS ( n=178 ) transobturator and/or retropubic sling ( n=178 ) treatment stress urinary incontinence 40 U.S. international site . Subjects follow total 36 month schedule visit 6 , 12 , 18 , 24 36 month . The study population consist adult female subject stress incontinence clinically indicate surgical intervention mesh sling .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Stress</mesh_term>
	<criteria>The subject female least 18 year age . The subject able willing complete procedure followup visit indicate protocol . The subject confirm stress urinary incontinence cough stress test urodynamics . The subject fail two noninvasive incontinence therapy ( Kegal exercise , behavior modification , pad use , biofeedback , etc . ) &gt; 6 month . The subject active urogenital infection active skin infection region surgery . The subject confirm Pelvic Organ Prolapse ( POP ) Stage 2 high determine POPQ prolapse grading . The subject concomitant pelvic floor procedure . The subject incontinence due neurological cause ( e.g . multiple sclerosis , spinal cord/brain injury , cerebrovascular accident , detrusorexternal sphincter dyssynergia , Parkinsons disease , similar condition ) . The subject prior surgical stress urinary incontinence treatment . The subject undergone radiation brachy therapy treat pelvic cancer . The subject urge predominant incontinence MESA assessment . The subject atonic bladder post void residual ( PVR ) 100 cc ≥ 2 occasion . The subject pregnant and/or plan get pregnant future . The subject contraindication surgical procedure product Instructions use ( IFU ) . The subject enrol concurrent clinical trial treatment ( drug device ) could affect continence function , without sponsor approval .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>stress urinary incontinence</keyword>
	<keyword>Altis 522</keyword>
	<keyword>urinary incontinence</keyword>
</DOC>